The Fort Worth Press - ZetrOZ Systems Extends Its Non-Invasive Knee Osteoarthritis Treatment to Orthopaedic Surgeons Across the United States

USD -
AED 3.672501
AFN 62.500568
ALL 81.665346
AMD 376.638512
ANG 1.789731
AOA 917.000289
ARS 1408.559701
AUD 1.407093
AWG 1.79625
AZN 1.733153
BAM 1.657732
BBD 2.015316
BDT 122.257492
BGN 1.647646
BHD 0.377044
BIF 2967.516369
BMD 1
BND 1.264006
BOB 6.914872
BRL 5.149738
BSD 1.000496
BTN 90.921882
BWP 13.147655
BYN 2.887753
BYR 19600
BZD 2.012349
CAD 1.36718
CDF 2154.99981
CHF 0.771925
CLF 0.021872
CLP 863.759693
CNY 6.841397
CNH 6.857315
COP 3766.41
CRC 473.565771
CUC 1
CUP 26.5
CVE 93.464598
CZK 20.54005
DJF 178.15505
DKK 6.33057
DOP 60.534914
DZD 129.987013
EGP 47.947598
ERN 15
ETB 155.037188
EUR 0.84722
FJD 2.194042
FKP 0.7407
GBP 0.74212
GEL 2.670154
GGP 0.7407
GHS 10.664305
GIP 0.7407
GMD 73.000029
GNF 8776.460716
GTQ 7.677286
GYD 209.254919
HKD 7.824345
HNL 26.478728
HRK 6.380402
HTG 131.214931
HUF 318.507496
IDR 16805
ILS 3.143435
IMP 0.7407
INR 91.04155
IQD 1310.649082
IRR 1314045.999943
ISK 121.420009
JEP 0.7407
JMD 155.878676
JOD 0.70899
JPY 155.859055
KES 128.949753
KGS 87.450213
KHR 4008.153786
KMF 418.000227
KPW 899.969408
KRW 1440.479757
KWD 0.30659
KYD 0.833856
KZT 499.237172
LAK 21431.332164
LBP 89582.475144
LKR 309.227757
LRD 183.588105
LSL 15.895271
LTL 2.95274
LVL 0.60489
LYD 6.321161
MAD 9.167108
MDL 17.129877
MGA 4228.425643
MKD 52.222651
MMK 2099.949955
MNT 3583.748993
MOP 8.059958
MRU 39.946941
MUR 46.370089
MVR 15.460254
MWK 1735.144917
MXN 17.188085
MYR 3.890978
MZN 63.905002
NAD 15.895271
NGN 1356.119634
NIO 36.819332
NOK 9.50965
NPR 145.47535
NZD 1.671355
OMR 0.384471
PAB 1.000504
PEN 3.356233
PGK 4.305082
PHP 57.689968
PKR 279.603921
PLN 3.57779
PYG 6443.891627
QAR 3.646026
RON 4.316604
RSD 99.48104
RUB 77.343793
RWF 1458.593085
SAR 3.750778
SBD 8.04851
SCR 13.66677
SDG 601.501353
SEK 9.047685
SGD 1.26571
SHP 0.750259
SLE 24.501945
SLL 20969.49935
SOS 570.767451
SRD 37.796991
STD 20697.981008
STN 20.765968
SVC 8.75642
SYP 110.55196
SZL 15.892322
THB 31.089816
TJS 9.505264
TMT 3.51
TND 2.878272
TOP 2.40776
TRY 43.959396
TTD 6.789229
TWD 31.388005
TZS 2551.162017
UAH 43.225845
UGX 3601.612131
UYU 38.30294
UZS 12134.191667
VES 410.571865
VND 26045
VUV 118.917841
WST 2.704188
XAF 555.98293
XAG 0.011145
XAU 0.000193
XCD 2.70255
XCG 1.803156
XDR 0.691464
XOF 555.985472
XPF 101.084501
YER 238.50998
ZAR 15.92681
ZMK 9001.19346
ZMW 18.73175
ZWL 321.999592
  • CMSD

    -0.0600

    23.53

    -0.25%

  • RYCEF

    -0.1900

    18.25

    -1.04%

  • CMSC

    -0.1399

    23.74

    -0.59%

  • RBGPF

    0.1000

    82.5

    +0.12%

  • GSK

    0.8600

    58.93

    +1.46%

  • NGG

    0.8350

    94.555

    +0.88%

  • RELX

    0.3500

    34.41

    +1.02%

  • BCE

    0.4800

    26.15

    +1.84%

  • VOD

    -0.0250

    15.375

    -0.16%

  • BCC

    -2.5800

    81.06

    -3.18%

  • BTI

    0.0100

    62.68

    +0.02%

  • RIO

    0.2650

    99.355

    +0.27%

  • BP

    0.6100

    38.6

    +1.58%

  • AZN

    4.4000

    208.38

    +2.11%

  • JRI

    0.0800

    13.25

    +0.6%

ZetrOZ Systems Extends Its Non-Invasive Knee Osteoarthritis Treatment to Orthopaedic Surgeons Across the United States
ZetrOZ Systems Extends Its Non-Invasive Knee Osteoarthritis Treatment to Orthopaedic Surgeons Across the United States

ZetrOZ Systems Extends Its Non-Invasive Knee Osteoarthritis Treatment to Orthopaedic Surgeons Across the United States

The active-aging healthcare innovators will showcase the sustained acoustic medicine device's effectiveness in treating knee osteoarthritis and soft tissue injuries, reducing pain and the need for invasive surgery.

Text size:

TRUMBULL, CT / ACCESS Newswire / February 27, 2026 / ZetrOZ Systems will showcase its sam® sustained acoustic medicine technology's effectiveness in treating knee osteoarthritis and other musculoskeletal conditions at the annual meeting of the American Academy of Orthopaedic Surgeons, March 3-5, in New Orleans.

The company will provide clinical information and demonstrate the sam® wearable ultrasound device at Booth 3612 in Hall E of the Ernest N. Morial Convention Center.

ZetrOZ Systems also is hosting AAOS conference attendees at an education event, Sam on the Rocks, at the Old Absinthe House's Prohibition Room at 240 Bourbon Street, from 5:00 p.m. to 7:00 p.m. on Tuesday, March 3.

Orthopaedic leaders and clinicians will learn how ZetrOZ Systems' wearable ultrasound technology has been integrated into real-world clinical practice. Attendees will also discover how the sam® units are helping shape the future of orthopaedic and sports medicine care.

Sustained acoustic medicine, via the sam® device, is continuous, high-frequency, long-duration ultrasound treatment applied directly to the site of an injury, increasing blood vessel diameters to improve blood flow. This increases oxygenated hemoglobin at the site and removes cytokine enzymes and cellular waste, resulting in more rapid healing and reduced pain.

The effectiveness of ZetrOZ Systems' technology has been validated in 42 peer-reviewed basic science, engineering and clinical publications and 20 Level 1-5 clinical studies. One study, published in the Journal of Orthopaedic Surgery and Research, found that "Sustained acoustic medicine (sam®), a multi-hour treatment, has demonstrated improved clinical outcomes for patients with knee OA."

The study concluded that "the sam® wearable home-use continuous long-duration ultrasound appears to be a cost-effective therapy and should be considered when treating patients with knee OA."

More than 3.7 million patient treatments demonstrate that ZetrOZ Systems' sustained acoustic medicine and the sam® wearable ultrasound devices reduce pain, improve function, and help people return to sports and daily activities. For more information about ZetrOZ Systems and the sam® wearable ultrasound device, visit www.zetroz.com or www.samrecover.com.

About ZetrOZ Systems

ZetrOZ Systems is a leader in sports medicine innovation, developing wearable bioelectronic devices that deliver sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on proprietary medical technology protected by 46 patents and is the exclusive manufacturer and developer of the sam® product line, designed to treat acute and chronic musculoskeletal conditions.

Media Contact

Catherine Hoblin
[email protected]

SOURCE: ZetrOZ Systems



View the original press release on ACCESS Newswire

T.Harrison--TFWP